The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...

In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive ...

In an advancement for diabetes management, the US Food and Drug Administration (FDA) has granted clearance to Medtronic’s new ...

The EC has granted approval to Novartis' Kisqali (ribociclib) plus an aromatase inhibitor to treat early breast cancer ...

Idorsia has extended its cash runway into 2025 via an exclusivity fee for global rights negotiations for Tryvio.

Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711.

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.